Grail Stock Rises on Optimism for FDA Approval and Insurance Coverage
Shares of Grail (GRAL) rose by 31.6% in May as investors reacted positively to the company's presentation at a major oncology conference, which is expected to bolster support for its Galleri test approval by the FDA and potential insurance coverage.
Tickers: $GRAL
Topics: cancer detection clinical trial results FDA approval Galleri test Grail